Go Pro
NASDAQ:HROW

Harrow (HROW) Stock Price, News & Analysis

Harrow logo
$34.07 -0.41 (-1.19%)
Closing price 09/14/2026 04:00 PM Eastern
Extended Trading
$33.97 -0.10 (-0.30%)
As of 05:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Harrow Stock (NASDAQ:HROW)

Advanced

Key Stats

Today's Range
$33.88
$35.33
50-Day Range
$34.07
$46.65
52-Week Range
$28.54
$54.85
Volume
524,034 shs
Average Volume
462,948 shs
Market Capitalization
$1.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.38
Consensus Rating
Moderate Buy

Company Overview

Harrow, Inc. is an ophthalmic pharmaceutical company focused on developing, acquiring, and commercializing products for the treatment of eye conditions and for use in ophthalmic procedures. The company serves ophthalmologists, optometrists, ambulatory surgery centers, and other eye-care providers, primarily in the United States.

Harrow’s portfolio includes VEVYE, a cyclosporine ophthalmic emulsion indicated for the treatment of signs and symptoms of dry eye disease, and IHEEZO, a chloroprocaine hydrochloride ophthalmic gel used to provide topical ocular anesthesia during ophthalmic procedures. The company also markets and develops additional prescription ophthalmic products and therapies through its commercial and pharmaceutical operations.

The company was founded as Harrow Health and later adopted the Harrow name as it expanded its ophthalmic pharmaceutical business. Harrow is headquartered in Nashville, Tennessee, and is led by founder and Chief Executive Officer Mark L. Baum.

AI Generated. May Contain Errors.

Harrow Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

HROW MarketRank™: 

Harrow scored higher than 46% of companies evaluated by MarketBeat, and ranked 599th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Harrow has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 9 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Harrow has a consensus price target of $66.38, representing about 94.8% upside from its current price of $34.07.

  • Amount of Analyst Coverage

    Harrow has only been the subject of 4 research reports in the past 90 days.

  • Read more about Harrow's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Harrow is -34.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Harrow is -34.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Harrow has a P/B Ratio of 24.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Harrow's valuation and earnings.
  • Percentage of Shares Shorted

    20.74% of the float of Harrow has been sold short.
  • Short Interest Ratio / Days to Cover

    Harrow has a short interest ratio ("days to cover") of 13.69, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Harrow has recently increased by 6.62%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Harrow does not currently pay a dividend.

  • Dividend Growth

    Harrow does not have a long track record of dividend growth.

  • News Sentiment

    Harrow has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Harrow this week, compared to 5 articles on an average week.
  • Search Interest

    Only 1 people have searched for HROW on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Harrow to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Harrow insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $450,000.00 in company stock.

  • Percentage Held by Insiders

    12.80% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Harrow's insider trading history.
Receive HROW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HROW Stock News Headlines

Harrow (NASDAQ:HROW) Research Coverage Started at Leerink Partners
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.tc pixel
Harrow (NASDAQ:HROW) Insider Sells 11,250 Shares of Stock
See More Headlines

HROW Stock Analysis - Frequently Asked Questions

Harrow's stock was trading at $49.00 at the beginning of the year. Since then, HROW stock has decreased by 30.5% and is now trading at $34.07.

Harrow, Inc. (NASDAQ:HROW) released its quarterly earnings data on Monday, August, 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.28. The company earned $70.66 million during the quarter, compared to analysts' expectations of $70.35 million. Harrow had a negative trailing twelve-month return on equity of 38.00% and a negative net margin of 13.51%.
Read the conference call transcript
.

Harrow's top institutional shareholders include BlackRock Inc. (7.35%), Opaleye Management Inc. (6.40%), California State Teachers Retirement System (4.31%) and Bamco Inc. NY (2.16%). Insiders that own company stock include Opaleye Management Inc, Mark L Baum, Andrew R Boll, Amir Shojaei and Adrienne L Graves.
View institutional ownership trends
.

Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Harrow investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Visa (V), Netflix (NFLX) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
8/10/2026
Today
9/14/2026
H.C. Wainwright 28th Annual Global Investment Conference
9/15/2026
Next Earnings (Estimated)
11/09/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:HROW
Previous Symbol
NASDAQ:HROW
CIK
1360214
Employees
373
Year Founded
2012

Price Target and Rating

High Price Target
$88.00
Low Price Target
$45.00
Potential Upside/Downside
+94.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$5.14 million
Net Margins
-13.51%
Pretax Margin
-12.13%
Return on Equity
-38.00%
Return on Assets
-3.37%

Debt

Debt-to-Equity Ratio
19.70
Current Ratio
2.24
Quick Ratio
2.08

Sales & Book Value

Annual Sales
$275.59 million
Price / Sales
4.63
Cash Flow
$0.85 per share
Price / Cash Flow
39.89
Book Value
$1.41 per share
Price / Book
24.16

Miscellaneous

Outstanding Shares
37,488,000
Free Float
32,690,000
Market Cap
$1.28 billion
Optionable
Optionable
Beta
0.24

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:HROW) was last updated on 9/15/2026 by MarketBeat.com Staff.
From Our Partners